436 companies

Alnylam Pharmaceuticals

Market Cap: US$37.6b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

ALNY

US$279.14

7D

-13.7%

1Y

-13.5%

Insmed

Market Cap: US$23.9b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

INSM

US$109.81

7D

-5.8%

1Y

5.0%

Summit Therapeutics

Market Cap: US$12.0b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

SMMT

US$15.07

7D

-4.0%

1Y

-46.7%

Ionis Pharmaceuticals

Market Cap: US$9.0b

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

IONS

US$54.65

7D

-15.0%

1Y

29.6%

Praxis Precision Medicines

Market Cap: US$8.9b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

PRAX

US$308.20

7D

-7.5%

1Y

461.0%

Vaxcyte

Market Cap: US$8.2b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

PCVX

US$56.04

7D

-6.3%

1Y

50.0%

ImmunityBio

Market Cap: US$8.1b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

IBRX

US$7.45

7D

-16.0%

1Y

163.3%

Oruka Therapeutics

Market Cap: US$5.3b

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

ORKA

US$86.65

7D

2.7%

1Y

485.5%

Veradermics

Market Cap: US$5.2b

A clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.

MANE

US$105.83

7D

-15.3%

1Y

n/a

CRISPR Therapeutics

Market Cap: US$5.0b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

CRSP

US$51.37

7D

-13.2%

1Y

-6.8%

Caris Life Sciences

Market Cap: US$4.9b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

CAI

US$16.48

7D

-7.8%

1Y

-47.3%

Celcuity

Market Cap: US$4.5b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

CELC

US$88.29

7D

-22.2%

1Y

542.1%

Legend Biotech

Market Cap: US$4.5b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

LEGN

US$22.71

7D

-17.1%

1Y

-46.1%

Viking Therapeutics

Market Cap: US$4.4b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

VKTX

US$36.37

7D

-11.6%

1Y

13.4%

Dyne Therapeutics

Market Cap: US$4.0b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

DYN

US$22.72

7D

-6.4%

1Y

141.7%

NewAmsterdam Pharma

Market Cap: US$3.9b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

NAMS

US$31.98

7D

-10.7%

1Y

52.9%

Structure Therapeutics

Market Cap: US$3.6b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

GPCR

US$49.62

7D

-9.6%

1Y

153.2%

Ultragenyx Pharmaceutical

Market Cap: US$3.1b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

RARE

US$30.22

7D

-12.7%

1Y

10.3%

Vera Therapeutics

Market Cap: US$3.1b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

VERA

US$42.50

7D

0.2%

1Y

80.4%

Beam Therapeutics

Market Cap: US$3.1b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

BEAM

US$28.39

7D

-20.7%

1Y

38.8%

Celldex Therapeutics

Market Cap: US$3.0b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

CLDX

US$35.40

7D

-9.2%

1Y

54.1%

uniQure

Market Cap: US$2.8b

Develops treatments for patients suffering from rare and other devastating diseases in the United States.

QURE

US$39.36

7D

-11.5%

1Y

158.9%

SELLAS Life Sciences Group

Market Cap: US$2.6b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

SLS

US$12.79

7D

-7.0%

1Y

566.1%

Immunome

Market Cap: US$2.6b

A biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

IMNM

US$22.20

7D

-8.2%

1Y

112.4%

Kailera Therapeutics

Market Cap: US$2.5b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

KLRA

US$18.32

7D

-12.8%

1Y

n/a

BioCryst Pharmaceuticals

Market Cap: US$2.5b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

BCRX

US$9.41

7D

-15.3%

1Y

9.5%

Tarsus Pharmaceuticals

Market Cap: US$2.5b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

TARS

US$57.69

7D

-10.1%

1Y

39.3%

Mineralys Therapeutics

Market Cap: US$2.4b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

MLYS

US$27.08

7D

-6.5%

1Y

88.8%

Nektar Therapeutics

Market Cap: US$2.3b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

NKTR

US$67.05

7D

-8.0%

1Y

151.4%

Biohaven

Market Cap: US$2.2b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

BHVN

US$14.17

7D

-15.6%

1Y

-6.2%

Zai Lab

Market Cap: US$2.2b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

ZLAB

US$20.44

7D

3.5%

1Y

-42.4%

Palvella Therapeutics

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

PVLA

US$151.97

7D

4.7%

1Y

434.7%

Ocular Therapeutix

Market Cap: US$2.1b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

OCUL

US$9.96

7D

-3.0%

1Y

-11.5%

Viridian Therapeutics

Market Cap: US$2.1b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

VRDN

US$18.03

7D

-10.7%

1Y

5.7%

AtaiBeckley

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

ATAI

US$5.36

7D

3.7%

1Y

98.5%

Syndax Pharmaceuticals

Market Cap: US$2.1b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

SNDX

US$22.71

7D

-8.6%

1Y

134.9%

Page 1 of 13